Top Markets
Coin of the day
Gamida Cell Ltd. Gamida Cell Ltd.

Gamida Cell Ltd.

GMDA
Classifica tra le azioni #35164
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated... Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
Prezzo delle azioni
$0.0327
Ultima sincronizzazione: 2025-06-17
Capitalizzazione di mercato
$4.34M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
IL
Scambia Gamida Cell Ltd. (GMDA)

Categoria

Storico del prezzo dell'azione per Gamida Cell Ltd. (GMDA)
Prezzo di chiusura più alto: $0.03 il 2025-06-01

Prezzo di chiusura più basso: $9.40 il 2018-10-01
Storico del prezzo dell'azione di Gamida Cell Ltd. dal 2018 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2025 117.76%
2024 -95.28%
2023 -75.22%
2022 -48.32%
2021 -71.87%
2020 84.95%
2019 -55.53%
2018 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE